Comparing the efficacy of nebulizer recombinant human DNase and hypertonic saline as monotherapy and combined treatment in the treatment of persistent atelectasis in mechanically ventilated newborns

Basit Öğe Kaydı
dc.contributor.authorAltunhan, Hüseyin
dc.contributor.authorAnnagür, Ali
dc.contributor.authorPekcan, Sevgi
dc.contributor.authorÖrs, Rahmi
dc.contributor.authorKoç, Hasan
dc.date.accessioned2020-03-26T18:24:23Z
dc.date.available2020-03-26T18:24:23Z
dc.date.issued2012
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractBackground: The purpose of the present study was to compare the cost-effectiveness and efficacy of nebulizer recombinant human DNase (rhDNase) and hypertonic saline (HS) as monotherapy and combined treatment in neonatal atelectasis. Methods: Eighty-seven newborns with persistent atelectasis who did not respond to traditional treatment were studied retrospectively. Group 1 did not receive nebulizer drugs; Group 2 received 7% HS; Group 3 received rhDNase; and Group 4 received both 7% HS and rhDNase. Subjects' chest X-ray scores, partial pressure of CO2, respiratory rate, fraction of inspired oxygen (FiO2) peak inspiratory pressure, atelectasis healing rate, median duration of nebulizer treatment and costs were compared. Results: Percentages of improvement in atelectasis on Day 3 of treatment in Group 1, Group 2, Group 3 and Group 4 were 27, 70, 81 and 95%, respectively, while median duration of treatment was 8.1, 3.3, 2.9 and 2.4 days, respectively. Comparison of chest X-ray scores, partial pressure of CO2, respiratory rate, FiO(2) and peak inspiratory pressure values before and 48 h after treatment did not yield a significant difference for the control group (P > 0.05), while a marked improvement was observed in other groups for all parameters (P < 0.05). The most distinct improvement was in Group 4, followed by Group 3. Conclusions: Although both the combined treatment with HS and rhDNase and their monotherapies are effective in the treatment of persistent atelectasis in newborns receiving mechanical ventilation, their combined use produces higher efficacy. The efficacy of rhDNase is superior to monotherapy with HS. Use of these two treatments concomitantly reduces the cost. To the best of our knowledge, the present study is the first to use HS alone or in combination with rhDNase in newborn patients.en_US
dc.identifier.doi10.1111/j.1442-200X.2011.03519.xen_US
dc.identifier.endpage136en_US
dc.identifier.issn1328-8067en_US
dc.identifier.issn1442-200Xen_US
dc.identifier.issue1en_US
dc.identifier.pmid22114907en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage131en_US
dc.identifier.urihttps://dx.doi.org/10.1111/j.1442-200X.2011.03519.x
dc.identifier.urihttps://hdl.handle.net/20.500.12395/27839
dc.identifier.volume54en_US
dc.identifier.wosWOS:000300671100025en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWILEYen_US
dc.relation.ispartofPEDIATRICS INTERNATIONALen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectatelectasisen_US
dc.subjectdornase alfaen_US
dc.subjecthypertonic salineen_US
dc.subjectnewbornen_US
dc.subjectrecombinant human DNaseen_US
dc.titleComparing the efficacy of nebulizer recombinant human DNase and hypertonic saline as monotherapy and combined treatment in the treatment of persistent atelectasis in mechanically ventilated newbornsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu